
Research interests
Our research aims to understand how oncogenic signaling pathways and interactions between tumor cells and the tumor immune microenvironment (TIME) drive lung cancer development and influence therapeutic responses. We focus on identifying the molecular and cellular mechanisms underlying tumor progression, immune escape and therapeutic vulnerabilities, with the ultimate goal of developing improved treatment strategies.
We primarily investigate KRAS- and EGFR-driven lung adenocarcinoma, two major molecular subtypes with distinct oncogenic drivers and therapeutic challenges.

KRAS-driven lung adenocarcinoma
We investigate therapeutic vulnerabilities in KRAS-driven tumors by studying oncogenic signaling pathways, cellular dependencies and metabolic adaptations. A particular focus is on understanding how KRAS-driven tumor cells shape the tumor immune microenvironment and how these interactions influence tumor progression and responses to immunotherapy, including immune checkpoint blockade.
EGFR-driven lung adenocarcinoma
We investigate the molecular and cellular mechanisms underlying tumor progression and responses to EGFR-targeted therapies. In particular, we study how tumor–immune interactions influence the persistence of residual tumor cells during treatment and their subsequent progression to relapse. Our aim is to identify immune mechanisms and therapeutic vulnerabilities that could improve the durability of targeted therapies.
Experimental approaches
Our research combines genetically engineered mouse models of human cancer, genetically modified human and mouse cancer cell lines, tumor transplantation models and human tumor specimens. These complementary approaches allow us to investigate tumor development, dissect tumor–immune interactions and evaluate novel therapeutic strategies.


Selected publications
Uras, IZ, et al., KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors. 2026. NPJ Precis Oncol. Available at: https://doi.org/10.1038/s41698-025-01242-8
Luca, AC, et al., Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma. 2025. Cancer Letters. Available at: https://doi.org/10.1016/j.canlet.2025.217733
Caratti, B. et al., 2022. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Science Signaling. Available at: DOI: 10.1126/scisignal.abm4452
Breitenecker, K. et al., 2021. Downregulation of A20 promotes immune escape of lung adenocarcinomas. Science Translational Medicine. Available at: https://doi.org/10.1126/scitranslmed.abc3911
Mohrherr, J. et al., 2019. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. International Journal of Cancer. Available at: https://doi.org/10.1002/ijc.32624
Moll, H.P. et al., 2018. Afatinib restrains K-RAS-driven lung tumorigenesis. Science Translational Medicine. Available at: http://dx.doi.org/10.1126/scitranslmed.aao2301
Grabner, B. et al., 2015. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications. Available at: http://dx.doi.org/10.1038/ncomms7285
Musteanu, M. et al., 2012. A mouse model to identify cooperating signaling pathways in cancer. Nature Methods. Available at: https://doi.org/10.1038/nmeth.2130
Group members

From left to right: Ritesh Narwal, Sadaf Keshavarz, Emilio Casanova, Faith David, Eva Putz, Lena Vlasitz, Masa Beres, Christoph Trenk, Marija Trkulja, Jaqueline Horvath, Herwig Moll, Sarah Trouvilliez, Aaron Rauscher, Pauline Sieger, Iris Uras, Michael Machtinger and Monika Homolya

Pauline goodbye cake party. 2026

Center retreat. 2026

Iris Uras received the Innovation Award from the Austrian Society of Oncology (OeGHO). Congratulations!!!. 2026

Yanira defending her diploma. Congratulations! 2026

Good bye party of Yanira and Kati. Good luck for the future. 2026

Sarah´s grant celebration! 2026

Iris Uras reciving the Dora Brücke-Teleky prize! 2026

Monika Homolya awarded with a travel grant! EACR 2026

EACR meeting, Budapest, 2026



Contact
Emilio Casanova
Medical University of Vienna
Center for Physiology and Pharmacology
Institute of Pharmacology, first floor
Währinger Str. 13a
A-1090 Vienna,
Austria
Phone: 43 1 40160 31341
Fax: 43 1 40160 931300



